Viewing nowCombinationGlicitamet Tablet 50/1000 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.

MFDS item code 202204581 · Approved 2022.12.21 · Insurance code 657308830
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used to help control blood sugar levels in patients with type 2 diabetes using sitagliptin and metformin together. It helps effectively manage blood sugar while following a dietary regimen and exercise. Therefore, this medication is beneficial for the treatment of type 2 diabetes.
For antidiabetic therapy, the dose of this medication should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medication should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Patients in whom this medication is contraindicated). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medication is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medication may begin at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with concomitant metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take the patient’s blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medication is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medication. Any change in treatment for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment Due to its metformin component, this medication should not be administered to patients with hepatic impairment (see Precautions for Use, 2. Patients in whom this medication is contraindicated).
This medication contains sitagliptin and metformin and is used for diabetes treatment. Severe allergic reactions may occur during treatment with this medication, so if symptoms such as skin rash, hives, or difficulty breathing occur, discontinue use immediately and consult a physician. There is a risk of developing severe inflammation of the pancreas (pancreatitis), so if symptoms such as abdominal pain, nausea, vomiting, or loss of appetite occur, inform a healthcare provider immediately. Patients with poor kidney function or suspected acute kidney injury should not take this medication, and regular kidney function tests should be performed. Patients with cardiovascular diseases such as heart failure or acute myocardial infarction should avoid this medication. Before and after examinations using radiocontrast iodine, this medication should be temporarily discontinued and should only be restarted after confirming normal kidney function. Women who are pregnant or may become pregnant, as well as breastfeeding women, should not take this medication. Irregular meals or vigorous exercise, along with the use of other medications, may increase the risk of hypoglycemia, so caution is required. This medication can cause hypoglycemia, particularly when used in combination with insulin or sulfonylurea agents, so blood sugar levels should be checked frequently and symptoms should be monitored. The metformin component can rarely cause a serious metabolic disorder called lactic acidosis, so use should be avoided in cases of dehydration, severe infections, liver function impairment, or excessive alcohol consumption. It is important to regularly perform blood tests and kidney function evaluations to check for abnormalities. If sudden muscle pain, joint pain, skin rash, or blisters occur during treatment with this medication, inform a doctor immediately. Alcohol consumption can increase the risk of side effects from this medication, so it is advisable to avoid drinking while on this medication. In the event of an overdose, visit a healthcare facility immediately for appropriate treatment, and blood dialysis may be performed if necessary to remove the drug. This medication is not recommended for use in children under 18 years of age as safety and efficacy have not been sufficiently demonstrated. In the elderly, kidney function may be impaired, so dosage adjustments should be made and kidney function should be regularly monitored.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in an airtight container to prevent air or moisture from entering and is best kept at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the effectiveness of the medication for a longer period.
Dark red oval film-coated tablet
56 tablets/box[(14 tablets/PTP x 4)], 30 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.